Another study conducted by the same group, using human prostate cancer cell lines, demonstrated the role of apigenin cells’ treatment (2.5 to 20 μM up to 16 h) in the suppression of NF-κB signaling through direct binding and consequent inhibition of IKKa [49]. Here, NFKB1 is linked to prostate cancer.